Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

NCT03116113 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03116113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03116113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)
Lead sponsor
Biogen
Phase
Phase 1/2
Overall status
Completed
Start date
March 8, 2017
Completion date
November 18, 2020
Enrollment
50 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked retinitis pigmentosa